Your browser doesn't support javascript.
Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.
Konig, Maximilian F; Gianfrancesco, Milena; Yazdany, Jinoos; Robinson, Philip C.
  • Konig MF; Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.
  • Gianfrancesco M; Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Yazdany J; Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Robinson PC; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.
Ann Rheum Dis ; 80(4): e55, 2021 04.
Article in English | MEDLINE | ID: covidwho-1546472
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Lupus Erythematosus, Systemic Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Lupus Erythematosus, Systemic Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article